Literature DB >> 11724083

Hepatotoxicity associated with carvedilol.

K O Hagmeyer1, J Stein.   

Abstract

OBJECTIVE: To report a severe episode of pruritus and elevated serum transaminases in a patient who was receiving carvedilol. CASE
SUMMARY: A 40-year-old white man who had been taking carvedilol for the treatment of cardiomyopathy presented to the emergency department with pruritus over his entire body. Laboratory tests showed elevated serum transaminases. Carvedilol was discontinued and the patient received hydroxyzine hydrochloride to relieve symptoms. Liver function test results returned to normal in three weeks. Approximately one year later the patient was started on metoprolol and within 10 days again developed pruritus. The patient was told to discontinue the metoprolol immediately. At the time the metoprolol was stopped the liver function test results were normal. DISCUSSION: To the best of our knowledge, the adverse reaction presented in this case report is rare. The etiology of this adverse reaction remains unknown but suggests a possible adverse reaction that may recur if the patient is switched to another beta-adrenergic blocker. The liver function test abnormalities appear to return to normal on discontinuation of carvedilol.
CONCLUSIONS: Carvedilol may cause pruritus and elevated liver function test results. This reaction may recur if the patient is changed to an alternative beta-adrenergic blocker. Patients taking carvedilol should be monitored for signs and symptoms of hepatotoxicity. If elevated liver function test results are noted, carvedilol should be discontinued.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724083     DOI: 10.1345/aph.10239

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

1.  Mechanisms of carvedilol-induced [Ca2+] i rises and death in human hepatoma cells.

Authors:  Jin-Shiung Cheng; Chorng-Chih Huang; Chiang-Ting Chou; Chung-Ren Jan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-05       Impact factor: 3.000

2.  The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase.

Authors:  Tiziana Cocco; Giuseppe Cutecchia; Grazia Montedoro; Michele Lorusso
Journal:  J Bioenerg Biomembr       Date:  2002-08       Impact factor: 2.945

3.  Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case.

Authors:  João Rua; Ana Rita Prata; Ricardo Marques; Rafael Silva; Bráulio Gomes; João Fraga; Jorge Fortuna
Journal:  GE Port J Gastroenterol       Date:  2018-07-10

Review 4.  Gastrointestinal Side Effects of Antiarrhythmic Medications: A Review of Current Literature.

Authors:  Waseem Amjad; Waqas Qureshi; Ali Farooq; Umair Sohail; Salma Khatoon; Sarah Pervaiz; Pratyusha Narra; Syeda M Hasan; Farman Ali; Aman Ullah; Steven Guttmann
Journal:  Cureus       Date:  2017-09-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.